Furthermore, high-risk patients exhibited excellent sensitivity to the combination of anti-PD-1 and anti-CTLA-4 immunotherapy (p < 0.001, Figure 11I), revealing the potential immunotherapy regimen for patients with advanced ccRCC. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.